NewsBite

The COVID-19 jackpot that eluded CSL

The COVID-19 jackpot that eluded CSL

CEO Paul Perreault faced a dilemma amid the rush to develop a vaccine for the coronavirus – one that resulted in the biggest disappointment of his career there.

Yolanda Redrup and Liam Walsh
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

CSL chief executive Paul Perreault faced a devil’s choice when it came to developing a COVID-19 vaccine during the height of the pandemic.

The biotechnology company was backing a vaccine from the University of Queensland, which was showing promise. But then a problem emerged in early-stage trials: the vaccine’s design had triggered false-positive results for HIV infections.

Loading...
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

License article

Read More

Yolanda Redrup
Yolanda RedrupRich List EditorYolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
Liam WalshReporterLiam Walsh writes on investigations and companies with The Australian Financial Review. He has won multiple media awards, worked in Japan and is now based in Brisbane. Email Liam at liam.walsh@afr.com.au

Latest In Healthcare & fitness

Fetching latest articles

Original URL: https://www.afr.com/companies/healthcare-and-fitness/the-covid-19-jackpot-that-eluded-csl-20230502-p5d4ya